Yair Lotan, MD
Dr. Lotan is a Professor of the Department of Urology at UT Southwestern and
Jane and John Justin Distinguished Chair in Urology,
In Honor of Claus G. Roehrborn, M.D. He is chief of urologic oncology. He graduated from Baylor College of Medicine and did his residency training at UT Southwestern Medical Center. His practice focuses on oncology and endourology. His research is focused on the areas of bladder cancer screening, biomarkers, decision analysis and health economics. Dr. Lotan has participated in multiple collaborative studies involving early detection of bladder cancer. Dr. Lotan is also PI on several investigator-initiated studies evaluating the role of urine and tissue markers in management of bladder cancer. He has published over 500 peer reviewed articles and has been invited to write multiple book chapters, reviews and editorials. He leads the disease oriented team for genitor-urinary malignancies at the UT Southwestern Simmons Cancer Center. He has participated in writing the AUA/ASCO/ASTRO muscle invasive bladder cancer guidelines. He is on editorial staff of other urologic journals. He was the chair of AUA Core Curriculum committee. He is also on the scientific advisory board of the Bladder Cancer Advocacy Network.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:storzDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:verity pharmaceuticalsDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ferring researchDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:seattle geneticsDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ambuDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Cleveland DiagnosticsDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:abbvieDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:fergeneDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:C2I genomicsDate added:Date updated:07/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BMSDate added:Date updated:07/15/2024